ARID1A: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Line 8: Line 8:
==Clinical significance==
==Clinical significance==
This gene has been commonly found mutated in gastric cancers,<ref name="pmid22037554">{{cite journal | vauthors = Wang K, Kan J, Yuen ST, Shi ST, Chu KM, Law S, Chan TL, Kan Z, Chan AS, Tsui WY, Lee SP, Ho SL, Chan AK, Cheng GH, Roberts PC, Rejto PA, Gibson NW, Pocalyko DJ, Mao M, Xu J, Leung SY | title = Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer | journal = Nat. Genet. | volume = 43 | issue = 12 | pages = 1219–23 |date=December 2011 | pmid = 22037554 | doi = 10.1038/ng.982 }}</ref> ovarian clear cell carcinoma,<ref name="pmid20942669">{{cite journal | vauthors = Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, Miller D, Jones SJ, Moore RA, Morin GB, Oloumi A, Boyd N, Aparicio SA, ((Shih I-M)), Mes-Masson AM, Bowtell DD, Hirst M, Gilks B, Marra MA, Huntsman DG | title = ARID1A mutations in endometriosis-associated ovarian carcinomas | journal = N. Engl. J. Med. | volume = 363 | issue = 16 | pages = 1532–43 |date=October 2010 | pmid = 20942669 | pmc = 2976679 | doi = 10.1056/NEJMoa1008433 }}</ref> and pancreatic cancer.<ref name="pmid22233809">{{cite journal | vauthors = Shain AH, Giacomini CP, Matsukuma K, Karikari CA, Bashyam MD, Hidalgo M, Maitra A, Pollack JR | title = Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer | journal = Proc. Natl. Acad. Sci. U.S.A. | volume = 109 | issue = 5 | pages = E252–9 |date=January 2012 | pmid = 22233809 | pmc = 3277150 | doi = 10.1073/pnas.1114817109 }}</ref>
This gene has been commonly found mutated in gastric cancers,<ref name="pmid22037554">{{cite journal | vauthors = Wang K, Kan J, Yuen ST, Shi ST, Chu KM, Law S, Chan TL, Kan Z, Chan AS, Tsui WY, Lee SP, Ho SL, Chan AK, Cheng GH, Roberts PC, Rejto PA, Gibson NW, Pocalyko DJ, Mao M, Xu J, Leung SY | title = Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer | journal = Nat. Genet. | volume = 43 | issue = 12 | pages = 1219–23 |date=December 2011 | pmid = 22037554 | doi = 10.1038/ng.982 }}</ref> ovarian clear cell carcinoma,<ref name="pmid20942669">{{cite journal | vauthors = Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, Miller D, Jones SJ, Moore RA, Morin GB, Oloumi A, Boyd N, Aparicio SA, ((Shih I-M)), Mes-Masson AM, Bowtell DD, Hirst M, Gilks B, Marra MA, Huntsman DG | title = ARID1A mutations in endometriosis-associated ovarian carcinomas | journal = N. Engl. J. Med. | volume = 363 | issue = 16 | pages = 1532–43 |date=October 2010 | pmid = 20942669 | pmc = 2976679 | doi = 10.1056/NEJMoa1008433 }}</ref> and pancreatic cancer.<ref name="pmid22233809">{{cite journal | vauthors = Shain AH, Giacomini CP, Matsukuma K, Karikari CA, Bashyam MD, Hidalgo M, Maitra A, Pollack JR | title = Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer | journal = Proc. Natl. Acad. Sci. U.S.A. | volume = 109 | issue = 5 | pages = E252–9 |date=January 2012 | pmid = 22233809 | pmc = 3277150 | doi = 10.1073/pnas.1114817109 }}</ref>
In breast cancer distant metastases acquire inactivation mutations in ARID1A not seen in the primary tumor, and reduced ARID1A expression confers resistance to different drugs such as trastuzumab and mTOR inhibitors. These findings provide a rationale for why tumors accumulate ARID1A mutations.<ref>"Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance". Berns K et al; ''Clin Cancer Res.'' 2016 Nov 1;22(21):5238-5248</ref><ref>"Genomic Evolution of Breast Cancer Metastasis and Relapse". Yates LR et al. ''Cancer Cell''. 2017 Aug 14;32(2):169-184.e7. doi: 10.1016/j.ccell.2017.07.005.</ref>
In breast cancer distant metastases acquire inactivation mutations in ARID1A not seen in the primary tumor, and reduced ARID1A expression confers resistance to different drugs such as trastuzumab and mTOR inhibitors. These findings provide a rationale for why tumors accumulate ARID1A mutations.<ref>"Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance". Berns K et al; ''Clin Cancer Res.'' 2016 Nov 1;22(21):5238-5248</ref><ref>{{doi|10.1016/j.ccell.2017.07.005.}}</ref>


==Research==
==Research==

Revision as of 20:25, 2 March 2020

ARID1A
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesARID1A, B120, BAF250, BAF250a, BM029, C1orf4, ELD, MRD14, OSA1, P270, SMARCF1, hELD, hOSA1, CSS2, AT-rich interaction domain 1A
External IDsOMIM: 603024 MGI: 1935147 HomoloGene: 21216 GeneCards: ARID1A
Orthologs
SpeciesHumanMouse
Entrez

8289

93760

Ensembl

ENSG00000117713

ENSMUSG00000007880

UniProt

O14497

A2BH40

RefSeq (mRNA)

NM_139135
NM_006015
NM_018450

NM_001080819
NM_001363070

RefSeq (protein)

NP_006006
NP_624361

Location (UCSC)Chr 1: 26.69 – 26.78 MbChr 4: 133.68 – 133.76 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

AT-rich interactive domain-containing protein 1A is a protein that in humans is encoded by the ARID1A gene.[5][6][7]

Function

ARID1A is a member of the SWI/SNF family, whose members have helicase and ATPase activities and are thought to regulate transcription of certain genes by altering the chromatin structure around those genes. The encoded protein is part of the large ATP-dependent chromatin remodelling complex SWI/SNF, which is required for transcriptional activation of genes normally repressed by chromatin. It possesses at least two conserved domains that could be important for its function. First, it has an ARID domain, which is a DNA-binding domain that can specifically bind an AT-rich DNA sequence known to be recognized by a SWI/SNF complex at the beta-globin locus. Second, the C-terminus of the protein can stimulate glucocorticoid receptor-dependent transcriptional activation. It is thought that the protein encoded by this gene confers specificity to the SWI/SNF complex and may recruit the complex to its targets through either protein-DNA or protein-protein interactions. Two transcript variants encoding different isoforms have been found for this gene.[7]

Clinical significance

This gene has been commonly found mutated in gastric cancers,[8] ovarian clear cell carcinoma,[9] and pancreatic cancer.[10] In breast cancer distant metastases acquire inactivation mutations in ARID1A not seen in the primary tumor, and reduced ARID1A expression confers resistance to different drugs such as trastuzumab and mTOR inhibitors. These findings provide a rationale for why tumors accumulate ARID1A mutations.[11][12]

Research

Lack of this gene/protein seems to protect rats from some types of liver damage.[13]

Interactions

ARID1A has been shown to interact with SMARCB1[14][15] and SMARCA4.[15][16]

References

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000117713 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000007880 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Takeuchi T, Furihata M, Heng HH, Sonobe H, Ohtsuki Y (Aug 1998). "Chromosomal mapping and expression of the human B120 gene". Gene. 213 (1–2): 189–93. doi:10.1016/S0378-1119(98)00194-2. PMID 9630625.
  6. ^ Takeuchi T, Chen BK, Qiu Y, Sonobe H, Ohtsuki Y (Feb 1998). "Molecular cloning and expression of a novel human cDNA containing CAG repeats". Gene. 204 (1–2): 71–7. doi:10.1016/S0378-1119(97)00525-8. PMID 9434167.
  7. ^ a b "Entrez Gene: ARID1A AT rich interactive domain 1A (SWI-like)".
  8. ^ Wang K, Kan J, Yuen ST, Shi ST, Chu KM, Law S, Chan TL, Kan Z, Chan AS, Tsui WY, Lee SP, Ho SL, Chan AK, Cheng GH, Roberts PC, Rejto PA, Gibson NW, Pocalyko DJ, Mao M, Xu J, Leung SY (December 2011). "Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer". Nat. Genet. 43 (12): 1219–23. doi:10.1038/ng.982. PMID 22037554.
  9. ^ Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, Miller D, Jones SJ, Moore RA, Morin GB, Oloumi A, Boyd N, Aparicio SA, Shih I-M, Mes-Masson AM, Bowtell DD, Hirst M, Gilks B, Marra MA, Huntsman DG (October 2010). "ARID1A mutations in endometriosis-associated ovarian carcinomas". N. Engl. J. Med. 363 (16): 1532–43. doi:10.1056/NEJMoa1008433. PMC 2976679. PMID 20942669.
  10. ^ Shain AH, Giacomini CP, Matsukuma K, Karikari CA, Bashyam MD, Hidalgo M, Maitra A, Pollack JR (January 2012). "Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer". Proc. Natl. Acad. Sci. U.S.A. 109 (5): E252–9. doi:10.1073/pnas.1114817109. PMC 3277150. PMID 22233809.
  11. ^ "Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance". Berns K et al; Clin Cancer Res. 2016 Nov 1;22(21):5238-5248
  12. ^ doi:10.1016/j.ccell.2017.07.005.
  13. ^ Tissue Regeneration Promoted through Gene Suppression. March 2016
  14. ^ Kato H, Tjernberg A, Zhang W, Krutchinsky AN, An W, Takeuchi T, Ohtsuki Y, Sugano S, de Bruijn DR, Chait BT, Roeder RG (February 2002). "SYT associates with human SNF/SWI complexes and the C-terminal region of its fusion partner SSX1 targets histones". J. Biol. Chem. 277 (7): 5498–505. doi:10.1074/jbc.M108702200. PMID 11734557.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  15. ^ a b Wang W, Côté J, Xue Y, Zhou S, Khavari PA, Biggar SR, Muchardt C, Kalpana GV, Goff SP, Yaniv M, Workman JL, Crabtree GR (October 1996). "Purification and biochemical heterogeneity of the mammalian SWI-SNF complex". EMBO J. 15 (19): 5370–82. doi:10.1002/j.1460-2075.1996.tb00921.x. PMC 452280. PMID 8895581.
  16. ^ Zhao K, Wang W, Rando OJ, Xue Y, Swiderek K, Kuo A, Crabtree GR (November 1998). "Rapid and phosphoinositol-dependent binding of the SWI/SNF-like BAF complex to chromatin after T lymphocyte receptor signaling". Cell. 95 (5): 625–36. doi:10.1016/S0092-8674(00)81633-5. PMID 9845365.

Further reading

External links

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

Retrieved from "https://en.wikipedia.org/w/index.php?title=ARID1A&oldid=943598673"